NanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShieldBusiness Wire • 03/28/24
NanoVibronix Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution OpportunityBusiness Wire • 12/04/23
NanoVibronix Announces Agreement for Clinical Study of UroShield at the University of MichiganBusiness Wire • 11/28/23
NanoVibronix UroShield Products Available on NHS Drug Tariff Effective November 1Business Wire • 11/07/23
NanoVibronix Gains Approval for Inclusion of UroShield Products in NHS Prescription Services' Drug TariffBusiness Wire • 09/27/23
NanoVibronix Announces Presentation of Positive Independent Testing Results of UroShield at ICS Annual MeetingBusiness Wire • 09/06/23
NanoVibronix Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq RulesBusiness Wire • 08/30/23
NanoVibronix Applies for Inclusion of UroShield Products in NHS Prescription Services' Drug TariffBusiness Wire • 08/28/23
NanoVibronix Extends Distribution Agreement with Its Largest Distributor for PainShield and PainShield PlusBusiness Wire • 08/23/23
NanoVibronix Announces Distribution Agreement with Sports Medicine Supplier Mio-GuardBusiness Wire • 06/14/23
NanoVibronix Receives Positive Final Results of Independent Lifecycle Testing of PainShield Prompted by Centers for Medicare and Medicaid Services (CMS)Business Wire • 03/28/23
NanoVibronix Announces Positive Results from Independent Product Trial of UroShield for Patients with a Spinal Cord InjuryBusiness Wire • 03/14/23